Secretolytic treatment in acute and chronic diseases of the upper respiratory tract, bronchi and lungs, connected with abnormal secretion and transport of mucus secretions. Preventive treatment of seasonal exacerbations of chronic bronchitis.
Composition:
One capsule contains 300 mg of erdostein. 1 sachet contains 225 mg of erdostein; 1 sachet contains 4 g of sucrose. After dissolving in water - 1 ml oral suspension contains 35 mg of erdostein; 2.5 ml of suspension contains 1 g of sucrose.
Action:
Preparation with mucolytic effect. Erdosteine is a prodrug, its active metabolites due to the presence of free thiol (-SH) groups break down disulfide bridges of polypeptide chains and mucoproteins present in the mucus secretion, which reduces the elasticity and viscosity of mucus and has a beneficial effect on mucociliary transport. In addition, they prevent the adhesion of bacteria to the airway epithelium, leading to a reduction of bacterial colonization and have a direct antioxidant effect: protect against α-1-antitrypsin - an enzyme that inhibits elastase activity, prevent reduction of chemotactic activity of polymorphonuclear granulocytes (effect caused by, among others, smoking) ) and prevent the oxidation of phenazone by tobacco smoke. After oral administration, erdostein is rapidly absorbed from the gastrointestinal tract, metabolized in the liver to three major metabolites containing free SH groups, the most active of which is the N-thiodiglycol homocysteine (M1) metabolite. The maximum concentration of erdostein and metabolite M1 in plasma occurs respectively after 1 and 3 hours. Erdosteine is bound to plasma proteins in about 64.5%, it is excreted mainly by the kidneys in the form of sulphates, a small part is excreted in the faeces.
Contraindications:
Hypersensitivity to the preparation ingredients or substances containing free SH groups. Hepatic impairment (eg increase in alkaline phosphatase and transaminases in the blood). Renal insufficiency (creatinine clearance <25 ml / min). Homocystinuria (erdostein is partially metabolised to homocysteine, and there is no data describing the administration of erdostein in patients with congenital disorders of amino acid metabolism, especially in patients on diet excluding methionine). Do not use the capsules and suspensions (225 mg) in children under 12 years of age. Suspensions (35 mg / ml) should not be used in children who have not reached the age of 2. Due to the content of aspartame, suspensions should not be used in patients with phenylketonuria.
Precautions:
Use cautiously in patients with weakened cough reflex or mucociliary transport disorders. Due to the sucrose content, the suspension should not be used in patients with fructose intolerance, sucrase-isomaltase deficiency or glucose-galactose malabsorption syndrome.
Pregnancy and lactation:
Due to the lack of tests, it is not recommended to use during pregnancy and breastfeeding.
Side effects:
The following may occur: epigastric pain, nausea, heartburn, headache; less frequently: constipation, diarrhea, dry mouth, dizziness, malaise, skin rash, urticaria, fever; in individual cases, a disorder or loss of taste in the initial phase of treatment.
Dosage:
Orally.capsules. Adults and children over 12 years of age: 1 capsule twice daily.Suspension (225 mg). Adults: 1 sachet 2-3 times a day. Children over 12 years of age: 10 mg / kg daily in 2 doses, 1 sachet twice daily.Suspension (35 mg / ml). Children after age 2: 10 mg / kg daily in 2 doses or children about the month 15-20 kg: 2.5 ml 2 times a day; 21-30 kg: 5 ml 2 times a day; > 30 kg: 7.5 ml 2 times a day. Preparations should not be used before bedtime.
(C)
